Erastin or sorafenib combined with small doses of cisplatin can effectively inhibit the growth of cisplatin-resistant NSCLC cells by inhibiting the Nrf2/SLC7A11 pathway (Li et al., 2020). Here, SLC7A11 is linked to non-small cell lung carcinoma.